|
|
|
|
|
|
|
28.10.26 - 21:06
|
Glaukos Announces Third Quarter 2026 Financial Results (Business Wire)
|
|
|
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2026. Key highlights include:
Record net sales of $211.0 million in Q3 2026 increased 58% year-over-year on a reported and constant currency basis.
U.S. Glaucoma record net sales of $118.6 million in Q3 2026 increased 47% year-over-year.
Corneal Health record net sales of $59.0 million in Q3 2026 increased 154% year-over-year.
Gross margin of approximately 85% and non-GAAP gross margin of approximately 88% in Q3 2026.
Net income of $2.0 million and non-GAAP net income of $28.5 million in Q3 2026.
Diluted earnings per share (EPS) of $0.03 and non-GAAP diluted EPS of $0.47 in Q3 2026.
Cash and cash equivalents, short-term investments, and restricted cash of $339.8 million at the end of Q3 2026, an increase...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
07.10.26 - 13:03
|
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28 (Business Wire)
|
|
|
Conference Call and Webcast Scheduled for 1:30 p.m. PTALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release third quarter 2026 financial results after the market close on Wednesday, October 28, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on October 28, 2026.
A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 833-461-5787 (U.S.) or 585-542-9983 (International) and enter Conference ID 517868366. A replay will be archived on the company's website following completion of the call.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
